Paulus, Walter J.

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction

Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology

Cardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

Cited by 3,564

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap

Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,003

Aortic stenosis

Carabello, B. A., & Paulus, W. J. (2009) · The Lancet

Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment Approaches

Cited by 818

Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension

van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., Ijsselmuiden, A. J. J., Schalkwijk, C. G., Bronzwaer, J. G. F., Diamant, M., et al. (2008) · Circulation

Cardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

Cited by 723

Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology

Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 708

Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes

Seferović, P. M., & Paulus, W. J. (2015) · European Heart Journal

Cardiovascular Function and Risk FactorsCardiomyopathy and Myosin Studies

Cited by 552

Cardiomyocyte stiffness in diastolic heart failure

Borbély, A., van der Velden, J., Papp, Z., Bronzwaer, J. G. F., Edes, I., Stienen, G. J. M., & Paulus, W. J. (2005) · Circulation

Cardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

Cited by 536

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

Lee, D. I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S.-H., Danner, T., Zhang, M., Rainer, P. P., et al. (2015) · Nature

Phosphodiesterase function and regulationCardiovascular Function and Risk Factors

Cited by 353

How are Cytokines Activated in Heart Failure?

Paulus, W. J. (1999) · European Journal of Heart Failure

Cardiac Fibrosis and RemodelingHeart Failure Treatment and Management

Cited by 72

NOX5 Expression Is Increased in Intramyocardial Blood Vessels and Cardiomyocytes after Acute Myocardial Infarction in Humans

Hahn, N. E., Meischl, C., Kawahara, T., Musters, R. J. P., Verhoef, V. M. J., van der Velden, J., Vonk, A. B. A., Paulus, W. J., van Rossum, A. C., Niessen, H. W. M., et al. (2012) · The American Journal of Pathology

Nitric Oxide and Endothelin EffectsCardiac Ischemia and Reperfusion

Cited by 67